Personalized and targeted therapies-Reference-Cited by-同舟云学术

Personalized and targeted therapies

Published:2021-04-20 Issue:0 Volume:0 Page:
ISSN:2365-6581
Container-title:Physical Sciences Reviews
language:en
Short-container-title:

Author:

Wiśniewska Magdalena¹²,Wiśniewski Michał³,Lewandowska Marzena A.⁴⁵⁶^ORCID

Affiliation:

1. Department of Oncology and Brachytherapy , Collegium Medicum Bydgoszcz, Nicolaus Copernicus University , Toruń , Poland

2. Department of Clinical Oncology , Oncology Centre , Bydgoszcz , Poland

3. Outpatient Chemotherapy Department , Oncology Centre , Bydgoszcz , Poland

4. Department of Thoracic Surgery and Tumors , Collegium Medicum Bydgoszcz, Nicolaus Copernicus University , Toruń , Poland

5. Oncology Centre , Bydgoszcz , Poland

6. Department of Molecular Oncology and Genetics , Innovative Medical Forum Oncology Centre , Bydgoszcz , Poland

Abstract

Abstract Biomarker is defined as indicator of normal or pathogenic biological process or response to an intervention or exposure. There are several categories of biomarkers but predictive biomarkers play the most important role in the treatment of neoplasms. In some cancers there may be more than one potential biomarker, and their identification determines the treatment of the patient. Identification of predictive biomarkers allows the development of novel targeted therapies resulting in tailored treatment. In this chapter we discuss most important predictive biomarkers used in contemporary oncology for which there is approved therapies.

Publisher

Walter de Gruyter GmbH

Subject

General Physics and Astronomy,General Materials Science,General Chemistry

Link

https://www.degruyter.com/document/doi/10.1515/psr-2019-0057/pdf

Reference120 articles.

1. Califf, RM. Biomarker definitions and their applications. Exp Biol Med 2018;243:213–21.

2. FDA-NIH Biomarker Working Group. BEST (biomarkers, endpointS, and other tools) resource. MD: Silver Spring; 2016.

3. Wasung, ME, Chawla, LS, Madero, M. Biomarkers of renal function, which and when? Clin Chim Acta 2015;438:350–7.

4. Scott, DW, Wright, GW, Williams, PM, Lih, C-J, Walsh, W, Jaffe, ES, et al.. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014;123:1214–17.

5. Sandler, HM, Eisenberger, MA. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol 2007;178:S20–24.